All In Biotech

Drug Trial Radar · NCT02013245

Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.

Phase I Double Blind, Randomized, Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC in Comparison With BCG in Elispot TB(ESAT-6, CFP10, PPD)- and HIV- Negative Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Jan 2013

Primary completion

Jun 2014

Study completion Nov 2014

Sponsor

Lead sponsor
Biofabri, S.LIndustry
Sponsor type
Industry
Collaborators
Universidad de Zaragoza; Centre Hospitalier Universitaire Vaudois; TuBerculosis Vaccine Initiative
First posted
Dec 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and immunogenicity of MTBVAC as a potential substitute for BCG vaccination. BCG vaccination has indeed demonstrated its major limitation in inducing protection against tuberculosis (TB). Novel vaccines are essential to fight against the current world epidemics in tuberculosis and resistance to anti-TB drugs.

Conditions

  • Tuberculosis
  • Healthy

Interventions

  • MTBVAC live vaccineBiological

    Live-attenuated Mycobacterium tuberculosis vaccine

  • Commercially available BCG live vaccineBiological

    Live-attenuated Mycobacterium bovis vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events up to 210 Days After VaccinationTime frame: 7 months follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Canton of Vaud, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.